Literature DB >> 26122624

Effects of fluoroquinolone restriction (from 2007 to 2012) on resistance in Enterobacteriaceae: interrupted time-series analysis.

J B Sarma1, B Marshall2, V Cleeve2, D Tate2, T Oswald2, S Woolfrey3.   

Abstract

BACKGROUND: Antibiotic stewardship is a key component in the effort to reduce healthcare-associated infections. AIM: To describe the implementation and analyse the impact of fluoroquinolone restriction on resistance in Enterobacteriaceae, focusing on urinary isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, which were historically almost universally resistant to fluoroquinolones.
METHODS: ESBL-producing E. coli hospital and community isolates, obtained between April 2009 and March 2012 from consecutive non-duplicate urine samples, were included in an interrupted time-series analysis based on a Poisson distribution model. Periods before and after fluoroquinolone restriction were compared. The trend in fluoroquinolone resistance in all urinary isolates of Enterobacteriaceae (N ≈ 20,000 per year) and blood culture isolates of E. coli (N ≈ 350) between 2009 and 2013 were also analysed.
FINDINGS: A large decline in the percentage of ciprofloxacin-resistant ESBL-producing urinary E. coli isolates was observed in both hospital (risk ratio: 0.473; 95% confidence interval: 0.315-0.712) and community settings (0.098; 0.062-0.157). The decline was also marked in all urinary isolates of Enterobacteriaceae and E. coli isolates from blood cultures.
CONCLUSION: We conclude that reducing fluoroquinolone usage to a level of ≤2 defined daily doses per 100 occupied bed-days in hospital sufficiently removed selection pressure to allow resistant Enterobacteriaceae – specifically, the UK endemic strains of ESBL-producing E. coli – to revert back to fluoroquinolone susceptibility within a short span of four months. This was accompanied with a concomitant reduction in overall ESBL burden.
Copyright © 2015 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial stewardship; Enterobacteriaceae; Fluoroquinolones; Interrupted time-series analysis

Mesh:

Substances:

Year:  2015        PMID: 26122624     DOI: 10.1016/j.jhin.2015.05.006

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  12 in total

1.  Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae.

Authors:  Matthias I Gröschel; Till F Omansen; Wiel de Lange; Tjip S van der Werf; Mariëtte Lokate; Erik Bathoorn; Onno W Akkerman; Ymkje Stienstra
Journal:  Am J Trop Med Hyg       Date:  2016-01-11       Impact factor: 2.345

Review 2.  Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention.

Authors:  Kimberly C Claeys; Teri L Hopkins; Ana D Vega; Emily L Heil
Journal:  Curr Infect Dis Rep       Date:  2018-03-23       Impact factor: 3.725

3.  Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.

Authors:  Hiroki Namikawa; Koichi Yamada; Hiroki Fujimoto; Ken-Ichi Oinuma; Yoshihiro Tochino; Yasuhiko Takemoto; Yukihiro Kaneko; Taichi Shuto; Hiroshi Kakeya
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

4.  Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015.

Authors:  Seung Yeon Song; Joo Hee Shin; Su Yeong Hyeon; Donguk Kim; Won Ku Kang; Soo-Han Choi; Yae-Jean Kim; Eun Young Kim
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

5.  The Effect of Antibiotic Restriction Programs on Prevalence of Antimicrobial Resistance: A Systematic Review and Meta-Analysis.

Authors:  Emelie C Schuts; Anders Boyd; Anouk E Muller; Johan W Mouton; Jan M Prins
Journal:  Open Forum Infect Dis       Date:  2021-02-13       Impact factor: 3.835

6.  Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae.

Authors:  Pierluigi Viale; Maddalena Giannella; Michele Bartoletti; Sara Tedeschi; Russell Lewis
Journal:  Infect Dis Ther       Date:  2015-09-11

7.  Aminoglycoside antibiotics for NIH category II chronic bacterial prostatitis: A single-cohort study with one-year follow-up.

Authors:  Vittorio Magri; Emanuele Montanari; Emanuela Marras; Gianpaolo Perletti
Journal:  Exp Ther Med       Date:  2016-08-30       Impact factor: 2.447

8.  Decreased Outpatient Fluoroquinolone Prescribing Using a Multimodal Antimicrobial Stewardship Initiative.

Authors:  Kevin Lin; Yorgo Zahlanie; Jessica K Ortwine; Norman S Mang; Wenjing Wei; L Steven Brown; Bonnie C Prokesch
Journal:  Open Forum Infect Dis       Date:  2020-05-21       Impact factor: 3.835

9.  Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014.

Authors:  Ping Yang; Yunbo Chen; Saiping Jiang; Ping Shen; Xiaoyang Lu; Yonghong Xiao
Journal:  BMC Infect Dis       Date:  2020-04-07       Impact factor: 3.090

10.  Restriction-free antimicrobial stewardship initiative targeting fluoroquinolone reduction across a regional health-system.

Authors:  Jacinta Chin; Sarah B Green; Lacie J McKamey; Michael D Gooch; Ryan W Chapin; Alyssa P Gould; Stephanie F Milliken; Lisa M Blanchette
Journal:  Infect Prev Pract       Date:  2019-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.